treatment of retinal vascular conditions and glaucoma.1-3 The portability and reliability of diode lasers confer ergonomic advantages over ion lasers; and the infrared emission wavelength has the biophysical advantages of good transmission through haemorrhagic media opacities and nuclear sclerotic cataract, together with negligible absorption within macular xanthophyll.45
The aims of the current study were to examine the potential range of applications of transscleral diode laser retinopexy in the treatment of surgical retinal conditions, to optimise treatment variables, and to assess whether this novel modality had significant advantages over conventional techniques.
Materials and methods

LASER
All treatments were performed using a semiconductor diode laser, with an emission wavelength of 810 nm (Iris Medical Instruments Inc, Mountain View, CA, USA). The maximum available power was 2 W and the exposure duration could be incrementally increased up to a maximum of 9 seconds. Laser delivery was accomplished via a transscleral probe, which was applied to the external scleral surface (Fig 1) .
The probe tip incorporated a 2 X 2 mm glass prism, which had a 1P5 mm diameter output face, to deliver laser energy perpendicular to the device handle and shaft. This means that within 1 mm from the output face of the prism, the laser illuminated spot did not change by more than 0 1 mm. A foot switch activated the laser and in all cases the desired visible end point was the greyish-white appearance typical of a threshold diode laser lesion. The strong forward scattering characteristics of sclera imply that the diameter of the treatment beam was not significantly increased during its passage through the sclera.
PATIENTS
A total of 36 eyes in 36 patients underwent diode laser retinopexy. The mean age was 47 (range 18-45) years and the mean period of review was 8 (range [4] [5] [6] [7] [8] [9] [10] [11] [12] months. There were a number of indications for transscleral diode laser retinopexy: (a) Retinal tears of up to 2 clock hours in extent, which were associated with retinal detachment (30 eyes). After drainage of subretinal fluid (where appropriate), each break was surrounded by two rows of laser bums. This was then followed by application of a scleral explant and, if necessary, air or gas injection.
(b) Irradiation of the site of drainage of subretinal fluid. In those cases of retinal detachment which required drainage (28 eyes), the technique of external suture needle drainage was applied.9 With the aim of inducing choroidal vascular closure and thus reducing the risk of drainage related haemorrhage, a pattern of 16 exposures was applied to the location selected for drainage.
(c) Giant retinal tears (six eyes). Tears of 3 clock hours or more in extent were treated with vitrectomy and silicone oil exchange. A double row of diode laser burns was administered to the posterior edge of the break and the 'horns' of the tear.
During treatments for these conditions, the initial power setting was 500 mW and the target area irradiated until a reaction was observed. The power was increased in 250 mW increments if a lesion was not observed after an exposure of up to 2-3 seconds. In those eyes with retinal tears and retinal detachments, effective chorioretinal lesions were produced with transscleral therapy (Fig  2) . Retinal reattachment was initially achieved in all the eyes, although the subsequent formation of new breaks required a second (nondiode) vitrectomy procedure in two eyes. In neither case was this thought to be a diode laser related complication. Punctate haemorrhages were observed at the centre of several lesions in three eyes, but reduction in power eliminated this effect in subsequent exposures.
Retinal burns 12 weeks after treatment appeared as pigmented scars. One eye had undergone prophylactic cryotherapy several years previously. In contrast with diode laser scars there was a greater amount of chorioretinal atrophy associated with the cryopexy scar (Fig 3) . Retinopexy before transscleral suture needle drainage of subretinal fluid was followed by drainage induced haemorrhage of 2-3 disc diameters in area in two of 28 eyes. No drainage related complications were observed in the remaining eyes (Fig 4) .
Retinal reattachment was achieved in all of the eyes treated for giant retinal tears. One striking feature was the mild degree of postoperative inflammation. The relatively extensive photocoagulation required induced relatively little intravitreal pigment dispersion or uveitis, in comparison with that commonly seen with extensive retinal cryotherapy. In one eye an excessively high power induced several punctate choroidal haemorrhages, but these had resolved by 2 weeks postoperatively.
Discussion
The results of this study suggest the potential of transscleral diode laser therapy in the treatment of surgical conditions of the retina and that there may be significant advantages over techniques currently employed.
The principal aims of retinal reattachment surgery are to appose the neurosensory retina to the underlying retinal pigment epithelium and create a chorioretinal adhesion around all retinal breaks. The three principal methods available to produce a chorioretinal scar are diathermy, cryotherapy, and photocoagulation. The ideal requirement of a transscleral delivery system is the ability to induce a focal tissue effect that is limited to the outer retina and inner choroid, with minimal damage to the inner retina, outer choroid, or sclera. The essential mechanism of action of retinal laser photocoagulation is the absorption of radiant energy by a chromophore, melanin, within the retinal pigment epithelium and choroid and its conversion to heat, with subsequent tissue coagulation. The initial coagulation, followed by secondary gliosis, accounts for the adhesive effect of lesions. The majority of lasers that are currently employed for this purpose emit radiation in the visible part of the electromagnetic spectrum -for example, the argon laser (emission wavelength 488-514-5 nm, blue-green). They have poor transmission properties through the sclera and their use is confined to transpupillary or intraocular systems of delivery. They are, therefore, of more limited effectiveness in the presence of media opacities or very peripheral pathology.
The recent introduction of lasers which emit in the near infrared region of the spectrum has allowed consideration of alternative delivery systems. The radiant emissions of the Nd:YAG laser (1064 nm) and the semiconductor diode laser (810 nm) have a combination of high scleral transmission and significant absorption within melanin. In contrast, several studies have demonstrated that argon laser irradiation is poorly transmitted through the sclera, even with indentation. Therefore, despite its higher absorption within melanin than the infrared wavelengths, it has not been considered appropriate for transscleral applications (Table 1, refs 13-15) . In relation to the diode laser, histological studies of transscleral irradiation demonstrated its ability to produce both ciliary body and chorioretinal lesions, but with no evidence of thermal damage to the sclera.7 16 High transmission through silicone explants may also be of advantage in the retreatment of eyes with retinal breaks (Nanda et al; poster presentation, ARVO, 1993) .
There is also evidence that diode laser retinopexy induces less pigment epithelial cell dispersion than cryotherapy, with important implications for the relative risks of induction of PVR following each form of therapy (Nissen et al; poster presentation, ARVO, 1993). Another study specifically compared bloodretinal barrier breakdown in rabbits induced by transscleral diode laser irradiation and retinal cryotherapy. Magnetic resonance imaging with gadolinium-DPTA enhancement of equal areas of treated retina demonstrated a twofold increase in signal enhancement in eyes treated with cryotherapy, compared with diode laser treated eyes. The difference in signal enhancement was correlated directly with change in permeability of the blood-retinal barrier (Arrindell et al; poster presentation, ARVO, 1992) .
In a pilot study, Haller and colleagues reported their success in employing transscleral diode laser retinopexy in retinal detachment surgery.8 Lesions were produced using energies which ranged between 234 and 1492 mJ (white patients) and 74 and 251 mJ (black patients), the differential energies being explained by pigmentary variation. Although generally higher radiant energies were employed in the present series, this may be explained by individual differences in fundal pigmentation, or the presence of retinal oedema, or haemorrhage.
The complication rate reported by Haller was low, being confined to pinpoint choroidal haemorrhages within lesions in three eyes and focal scleral discoloration in two eyes. These incidents were both attributed to employment of an excessively higher power. Despite the limited sample sizes in that and the current study, the low incidence of PVR following transscleral diode laser therapy is encouraging. In particular, the management of giant retinal tears requires relatively extensive areas of treatment and therefore the employment of a transscleral laser in preference to cryotherapy may minimise intravitreal dispersion of the cellular and humoral precursors of PVR.
The use of suture needle drainage of subretinal fluid obviates the risk of retinal incarceration that may follow scleral dissection and choroidal perforation. The inability to directly cauterise the choroid does introduce the risk of inducing a choroidal haemorrhage. A recent animal study demonstrated the efficacy of transscleral diode laser retinopexy in achieving choroidal vascular stasis sufficient to prevent haemorrhage following passage of a 20 gauge needle through the irradiated areas (Kaplan et al; poster presentation, ARVO, 1993). The low incidence of haemorrhagic complications of drainage in the present study tends to confirm these findings. The procedure is easy to perform, the only potential difficulty being in visualisation of choroidal lesions in the presence of deep or turbid subretinal fluid.
The successful deployment of the transscleral probe requires awareness of its differences from retinal cryotherapy. It 
